Lifestyle changes associated with the use of GLP-1 agonists and SGLT2 inhibitors are recommended for the treatment of obesity and T2DM in women, with beneficial effects on weight reduction and metabolic parameters. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.